Table 2 Univariable and multivariable analyses for LUAD validation datasets with p < 0.05 in univariate analyses for hypoxia and clinico-pathological variables available.
From: Development and validation of a hypoxia-associated signature for lung adenocarcinoma
Univariable | Multivariable | |||
|---|---|---|---|---|
HR [95% CI] | p | HR [95% CI] | p | |
GSE31210 (overall survival) (n = 204) | ||||
Hypoxia | 4.72 [1.63–13.7] | 0.0016 | 3.72 [1.26–11.01] | 0.02 |
Stage (II vs I) | 4.07 [1.90–8.70] | 0.00009 | 2.71 [1.23–5.96] | 0.014 |
Age (continuous) | 1.02 [0.96–1.07] | 0.60 | ||
Male | 2.24 [1.02–4.88] | 0.04 | 1.36 [0.50–3.68] | 0.55 |
Smoker (never) | 0.40 [0.18–0.88] | 0.02 | 0.55 [0.20–1.54] | 0.26 |
GSE72094 (overall survival) (n = 398) | ||||
Hypoxia | 1.70 [1.11–2.61] | 0.014 | 1.57 [1.02–2.41] | 0.04 |
Stage (III&IV vs I&II) | 2.56 [1.72–3.82] | 0.000002 | 2.78 [1.85–4.18] | 0.0000009 |
Age (continuous) | 1.01 [0.99–1.03] | 0.50 | ||
Male | 1.55 [1.07–2.25] | 0.02 | 1.74 [1.19–2.54] | 0.004 |
Smoker (never) | 0.73 [0.32–1.68] | 0.50 | ||
GSE50081 (overall survival) (n = 127) | ||||
Hypoxia | 2.05 [1.01–4.15] | 0.042 | 1.91 [0.94–3.88] | 0.07 |
Stage (II vs I) | 2.19 [1.19–4.04] | 0.009 | 2.06 [1.12–3.80] | 0.02 |
Age (continuous) | 1.02 [0.99–1.06] | 0.10 | ||
Male | 1.53[0.83–2.81] | 0.20 | ||
Smoker (never) | 0.41 [0.14–1.13] | 0.07 | ||
